Literature DB >> 30649682

Contraception methods used by women with rheumatoid arthritis and psoriatic arthritis.

David L Leverenz1, Amanda M Eudy2, Malithi Jayasundara2, Tayseer Haroun2, Gary McDaniel2, W Benjamin Nowell3, Jeffrey R Curtis4, Rachelle Crow-Hercher3, Whitney White3,5, Seth Ginsberg3, Megan E B Clowse2.   

Abstract

Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are common in women of childbearing age and are often treated with teratogenic medications. In this study, we assessed contraceptive methods in young women with RA or PsA and correlated contraceptive method efficacy with use of concomitant rheumatic medications. We combined the data from several cross-sectional surveys of women under the age of 40 with RA or PsA. Two surveys recruited participants from a clinic setting (RA and PsA Clinic Surveys), and the third survey recruited participants from CreakyJoints.org , an online forum for patients with inflammatory arthritis (CreakyJoints Survey). Of the 164 women included, 138 had RA (67 in RA Clinic Survey, 71 in CreakyJoints Survey) and 26 had PsA (19 in PsA Clinic Survey, 7 in CreakyJoints Survey). Use of specific contraceptive and rheumatic medications were similar between the clinic and online surveys. In the pooled analysis of the Clinic and CreakyJoints survey data, women with RA and PsA reported similar utilization of highly effective contraception methods (31.9% RA, 34.6% PsA) and effective methods (31.2% RA, 30.8% PsA), but different utilization of ineffective methods (35.5% RA, 11.5% PsA) and no methods (1.5% RA, 23.1% PsA), p = 0.0002. These proportions remained similar across subgroups taking methotrexate, anti-TNF biologics, and novel medications. Approximately two thirds of women with RA and PsA reported using effective or highly effective methods of contraception, though women with PsA were more likely to report no methods of contraception.

Entities:  

Keywords:  Contraception; Fertility; Psoriatic arthritis; Rheumatoid arthritis

Mesh:

Substances:

Year:  2019        PMID: 30649682     DOI: 10.1007/s10067-018-04420-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  13 in total

Review 1.  Managing contraception and pregnancy in the rheumatologic diseases.

Authors:  Megan E B Clowse
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-06       Impact factor: 4.098

2.  Comparing female-based contraceptive methods in patients with systemic lupus erythematosus, rheumatoid arthritis and a healthy population.

Authors:  Ediz Dalkilic; Ayse Nur Tufan; Mustafa Ferhat Oksuz; Mustafa Sahbazlar; Belkis Nihan Coskun; Nihan Seniz; Yavuz Pehlivan; Murat Inanc
Journal:  Int J Rheum Dis       Date:  2014-03-27       Impact factor: 2.454

Review 3.  State of the art: Reproduction and pregnancy in rheumatic diseases.

Authors:  Monika Østensen; Laura Andreoli; Antonio Brucato; Irene Cetin; Christina Chambers; Megan E B Clowse; Nathalie Costedoat-Chalumeau; Maurizio Cutolo; Radboud Dolhain; M H Fenstad; Frauke Förger; Marie Wahren-Herlenius; Guillermo Ruiz-Irastorza; Hege Koksvik; Catherine Nelson-Piercy; Yehuda Shoenfeld; Angela Tincani; Peter M Villiger; Marianne Wallenius; Michael von Wolff
Journal:  Autoimmun Rev       Date:  2014-12-30       Impact factor: 9.754

Review 4.  A multi-dimensional health assessment questionnaire (MDHAQ) and routine assessment of patient index data (RAPID3) scores are informative in patients with all rheumatic diseases.

Authors:  Theodore Pincus; Anca Dinu Askanase; Christopher J Swearingen
Journal:  Rheum Dis Clin North Am       Date:  2009-11       Impact factor: 2.670

5.  Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort.

Authors:  Laura C Coates; William Tillett; Gavin Shaddick; Theodore Pincus; Arthur Kavanaugh; Philip S Helliwell
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-06-28       Impact factor: 4.794

6.  U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.

Authors:  Kathryn M Curtis; Naomi K Tepper; Tara C Jatlaoui; Erin Berry-Bibee; Leah G Horton; Lauren B Zapata; Katharine B Simmons; H Pamela Pagano; Denise J Jamieson; Maura K Whiteman
Journal:  MMWR Recomm Rep       Date:  2016-07-29

7.  Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease.

Authors:  Monika Østensen; Mathias von Esebeck; Peter M Villiger
Journal:  J Rheumatol       Date:  2007-05-15       Impact factor: 4.666

8.  Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study.

Authors:  Corinna Weber-Schoendorfer; Christina Chambers; Evelin Wacker; Delphine Beghin; Nathalie Bernard; Svetlana Shechtman; Diana Johnson; Benedikte Cuppers-Maarschalkerweerd; Alessandra Pistelli; Maurizio Clementi; Ursula Winterfeld; Georgios Eleftheriou; Anna Pupco; Kelly Kao; Heli Malm; Elisabeth Elefant; Gideon Koren; Thierry Vial; Asher Ornoy; Reinhard Meister; Christof Schaefer
Journal:  Arthritis Rheumatol       Date:  2014-05       Impact factor: 10.995

9.  Contraception Use Among Reproductive-Age Women With Rheumatic Diseases.

Authors:  Mehret Birru Talabi; Megan E B Clowse; Susan J Blalock; Larry Moreland; Nalyn Siripong; Sonya Borrero
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-07-03       Impact factor: 4.794

10.  Increasing contraception use among women receiving teratogenic medications in a rheumatology clinic.

Authors:  Rebecca E Sadun; Melissa A Wells; Stephen J Balevic; Victoria Lackey; Erica J Aldridge; Nicholas Holdgagte; Samya Mohammad; Lisa G Criscione-Schreiber; Megan E B Clowse; Mamata Yanamadala
Journal:  BMJ Open Qual       Date:  2018-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.